ACE ImmunoIDTM

Neoantigen Detection
for Personalized Cancer Vaccines

Neoantigen Detection 2017-04-03T11:34:01+00:00

ACE ImmunoID for Neoantigen Detection

Improved detection of true somatic mutations
Comprehensive profiling and reporting of SNVs, InDels, gene expression, and novel fusion events
Analytically validated assays
2-week expedited turnaround time

Neoantigens—newly formed peptide fragments arising from mutated proteins in tumor cells—are unique to each patient and difficult to detect. Capturing an accurate view of the neoantigen landscape requires evaluation of the patient’s whole exome and whole transcriptome. However, most commercially available solutions fall short in terms of breadth and accuracy.

Comprehensive genomic and transcriptomic data for neoantigen detection

Personalis has developed an end-to-end platform for the development of personalized cancer vaccines, ACE ImmunoID for Neoantigen Detection. Designed for immuno-oncology clinical trials, the ACE ImmunoID platform offers whole exome and whole transcriptome sequencing with the ACE Cancer Exome and ACE Cancer Transcriptome assays. These assays provide coverage of >20,000 genes with enhanced coverage of >8,000 biomedically-relevant genes, of which >1,400 are cancer-related genes.

ACE Cancer Exome

The Personalis ACE Cancer Exome provides targeted sequencing to augment coverage gaps present in typical exomes. For example, the PRDX5 gene is reported to harbor variants that result in immunogenic epitopes, the part of an antigen recognized by the immune system. Figure 1 below highlights superior, uniform coverage of exonic regions with the ACE Cancer Exome (green) compared to the most widely used standard exome (blue) for clinical and translational research. Personalis returns the standard exome (blue) plus the enhanced exome (green). Variants residing in green regions (red rectangles) would be missed with a standard exome platform. ACE Cancer Exome assays allow accurate detection of true somatic mutations in tumors to guide neoantigen detection, especially in difficult-to-sequence genomic regions, such as regions with high guanine-cytosine (GC) content.

PRDX5-Sequence-ChartFigure 1. PRDX5 gene showing enhanced coverage using the ACE Cancer Exome.

ACE Cancer Transcriptome

The same accuracy and coverage are available for RNA analysis with our ACE Cancer Transcriptome enrichment protocol. When compared to a standard exome enrichment protocol, the ACE Cancer Transcriptome shows more uniform and deeper coverage across the entire gene (see Figure 2), including >95% of bases in exonic regions. In addition, because we use the most current gene definitions, the ACE Cancer Transcriptome covers exons that are missing in the standard annotation and other exon capture methods (Figure 3).

improved_coverage

Ready to accelerate the development of your personalized cancer vaccines?

To learn more about how we can help accelerate your immuno-oncology strategy, complete the form above or contact us at info@personalis.com.